Abstract
We previously demonstrated that ketoconazole is a potent inhibitor of triazolam biotransformation in vitro and in vivo. Despite significant elevations in triazolam plasma levels with coadministration of ketoconazole, the pharmacodynamic enhancement was lower than predicted based on plasma levels of triazolam. The present study examines the effects of ketoconazole on benzodiazepine receptor binding in vitro as well as on open-field behavior in male CD-1 mice. Triazolam alone inhibited [3H]flunitrazepam binding with an IC50 value of 0.85 nM and a Ki value of 0.50 nM. Ketoconazole alone also competitively antagonized [3H]flunitrazepam binding in a concentration-dependent manner with an IC50 value of 1.56 μM and aKi value of 1.17 μM. In the presence of 1, 3 or 9 μM ketoconazole, the IC50 value of triazolam was increased to 1.11, 1.58 and 5.73 nM, respectively, whereas maximal binding was reduced by 36%, 69% and 89%. Coadministration of 50 mg/kg ketoconazole and triazolam (0.1–0.3 mg/kg) to intact animals significantly elevated plasma and brain triazolam levels. Ketoconazole could be measured in mouse brain at levels averaging 31% of those in plasma. Ketoconazole alone had minimal or no effect on open field activity, but it significantly potentiated the decreased activity seen with triazolam administration. The ability of ketoconazole to inhibit triazolam displacement of [3H]flunitrazepam binding may explain the muted pharmacodynamic effect of this benzodiazepine in the presence of ketoconazole. Based on these results, it is likely that ketoconazole acts as a neutral ligand at the benzodiazepine receptor.
Footnotes
-
Send reprint requests to: Dr. David J. Greenblatt, Department of Pharmacology and Experimental Therapeutics, Tufts University School of Medicine, 136 Harrison Avenue, Boston, MA 02111.
-
↵1 This work was supported by Grants DA-05258, MH-34223, MH-01237 and MH-19924 from the Department of Health and Human Services. Dr. von Moltke is the recipient of a Scientist Development Award (K21-MH-01237) from the National Institute of Mental Health.
- Abbreviations:
- Bmax
- receptor density
- PEG 400
- polyethylene glycol 400
- Vmax
- maximum reaction velocity in vitro
- HPLC
- high-performance liquid chromatography
- S0.5
- substrate concentration corresponding to a reaction velocity of 50% Vmax
- IC50
- inhibitor concentration reducing reaction velocity or receptor binding to 50% of control
- Received June 25, 1997.
- Accepted December 15, 1997.
- The American Society for Pharmacology and Experimental Therapeutics
JPET articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|